Rigel Pharmaceuticals Inc
RIGL
Company Profile
Business description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Contact
611 Gateway Boulevard
Suite 900
South San Francisco CA 94080
USAT: +1 650 624-1100
E: ir@rigel.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
147
Stocks News & Analysis
stocks
2 ASX shares to avoid after results
These shares are trading at levels that are materially overvalued.
stocks
Strong results from IPO bolter not enough to change our view
Guzman's business has made an impressive start to the new fiscal year. We still have our doubts on valuation levels.
stocks
No sign of AI slowdown for Nvidia
Morningstar maintains our fair value estimate after latest earnings.
Morningstar Investment Ideas
Stocks
ETFs
- Australian ETFs
- Active Australian Equity ETFs
- Passive Australian Equity ETFs
- Emerging Market Equity ETFs
- Sustainable ETFs
- Active Global Equity ETFs
- Passive Global Equity ETFs
- Active Australian Fixed Interest ETFs
- Passive Australian Fixed Interest ETFs
- Active Australian Listed Property ETFs
- Passive Australian Listed Property ETFs
- Active Global Fixed Interest ETFs
- Passive Global Fixed Interest ETFs
- Active Global Infrastructure ETFs
- Passive Global Infrastructure ETFs
- Active Global Property ETFs
- Passive Global Property ETFs
Funds
- Active Australian Equity Funds
- Passive Australian Equity Funds
- Active Global Equity Funds
- Passive Global Equity Funds
- Sustainable Funds
- Emerging Market Equity Funds
- Passive Australian Listed Property Funds
- Active Australian Listed Property Funds
- Passive Global Infrastructure Funds
- Active Global Infrastructure Funds
- Active Global Property Funds
- Passive Global Property Funds
- Active Australian Fixed Interest Funds
- Passive Australian Fixed Interest Funds
- Active Global Fixed Interest Funds
- Passive Global Fixed Interest Funds
Markets
Index
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| All Ordinaries | 8,316.70 | 53.10 | 0.64% |
| CAC 40 | 7,630.95 | 10.00 | -0.13% |
| DAX 40 | 18,906.92 | 5.65 | -0.03% |
| Dow JONES (US) | 41,563.08 | 228.03 | 0.55% |
| FTSE 100 | 8,376.63 | 3.01 | -0.04% |
| HKSE | 17,989.07 | 202.75 | 1.14% |
| NASDAQ | 17,713.62 | 197.19 | 1.13% |
| Nikkei 225 | 38,647.75 | 285.22 | 0.74% |
| NZX 50 Index | 12,447.68 | 94.07 | 0.76% |
| S&P 500 | 5,648.40 | 56.44 | 1.01% |
| S&P/ASX 200 | 8,091.90 | 46.80 | 0.58% |
| SSE Composite Index | 2,842.21 | 19.11 | 0.68% |
Market Movers
Name
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| Aurizon Holdings Ltd AZJ | 3.38 | 0.00 | 0.00% |
| Latin Resources Ltd LRS | 0.20 | 0.01 | -2.44% |
| Red 5 Ltd RED | 0.34 | 0.02 | 6.25% |
| Droneshield Ltd DRO | 1.33 | 0.09 | 7.29% |
| Mesoblast Ltd MSB | 1.03 | 0.08 | 8.42% |
| Spartan Resources Ltd SPR | 1.46 | 0.16 | 12.36% |
| Telstra Group Ltd TLS | 3.93 | 0.02 | 0.51% |
| Pilbara Minerals Ltd PLS | 2.97 | 0.06 | 2.06% |
| Appen Ltd APX | 1.00 | 0.22 | -17.70% |
| South32 Ltd S32 | 3.14 | 0.04 | 1.29% |